Original Research Article

Effect of benzalkonium chloride-preserved latanoprost and benzalkonium chloride-free latanoprost on intraocular pressure in patients of primary open angle glaucoma

Anjleen Kaur¹, Shikha Palta¹, Hema Chhabra¹*, Gursatinder Singh², Anita Gupta¹

¹Department of Pharmacology, ²Department of Ophthalmology, Government Medical College, Patiala, Punjab, India

Received: 15 April 2018
Accepted: 04 May 2018

*Correspondence:
Dr. Hema Chhabra,
E-mail: hemachhabra@rediffmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: To evaluate the change in mean IOP with BKC-preserved latanoprost versus BKC-free latanoprost in patients of primary open angle glaucoma (POAG).

Methods: This was an open-label, randomized, interventional, switch trial. Thirty patients of primary open angle glaucoma (POAG) who were already on benzalkonium chloride (BKC)-preserved latanoprost for a minimum of three months were recruited. Their intraocular pressure (IOP) was recorded at the baseline. Then, they were switched over to benzalkonium chloride (BKC)-free latanoprost for another three months. Their intraocular pressure (IOP) was recorded at both 6 and 12 weeks of follow-up.

Results: IOP decreased from 15.57±0.85mm Hg at baseline to 15.40±0.89mm Hg at 6 weeks to 15.30±0.70mm Hg at 12 weeks. p value was found to be 0.209 and 0.115 at 6 and 12 weeks respectively. No statistically significant change was observed between mean IOP at both 6 and 12 weeks as compared to the baseline.

Conclusions: BKC-free medications have equal IOP lowering effect as BKC-preserved medications in glaucoma patients.

Keywords: Benzalkonium chloride-preserved latanoprost, Benzalkonium chloride-free latanoprost, Glaucoma, Latanoprost, Ocular surface disease

INTRODUCTION

Glaucoma is a chronic and progressive ocular disorder characterized by damage of optic nerve and retinal ganglion cells leading to blindness if not treated.¹ Medical therapy is the essence of glaucoma treatment and is the first line of management in open angle glaucoma.² These topical medications contain preservatives for increasing their shelf-lives and to prevent them from any kind of contamination.³ One such commonly used preservative is benzalkonium-chloride (BKC).⁴ Regular use of preserved therapies has led to the emergence of ocular surface disease (OSD) in glaucoma patients.⁵ Burning or stinging sensation, discharge, pain, irritation, dryness and foreign body sensation are some of the common complaints.⁶ BKC is the major etiological agent behind OSD which has been proved in various in vivo and in vitro studies.⁷⁻¹² BKC-free therapies have been observed to be healthy and safe for ocular surface health of glaucoma patients but are they equally effective in IOP lowering too?⁵,¹³⁻¹⁵ The major objective of this study was thus to evaluate the change in mean IOP with BKC-preserved latanoprost versus BKC-free latanoprost in patients of primary open angle glaucoma (POAG).

METHODS

The present study was done at Ophthalmology outpatient department, Rajindra hospital, Patiala. It was an open-label, randomized, interventional, switch trial. The study
was registered at Clinical Trial Registry- India (CTRI.nic.in identifier: CTRI/2016/06/007001) and the World Health Organization (Universal Trial Number: U1111-1165-4913). After approval of the institutional ethics committee (IEC) and written informed consent, thirty patients of primary open angle glaucoma (POAG) who were already on benzalkonium chloride (BKC)-preserved latanoprost for a minimum of three months were recruited. Complete patient history was taken and ocular examination was done. The patients who had a history of ocular surgery or trauma in the previous year, concurrent conjunctivitis, keratitis or uveitis, any clinically significant systemic disease was excluded from the study. The patients who fulfilled the inclusion criteria were enrolled in the study. Their IOP was recorded at the baseline using Goldmann applanation tonometer. The patients were then switched to BKC-free latanoprost. At 6 and 12 weeks of follow-up, their IOP was recorded again. Statistical analysis was done by SPSS software version 20.0. Paired t test was used for quantitative variables and chi square test for qualitative variables. p value less than 0.05 was taken as statistically significant.

RESULTS
In the present study, thirty patients of primary open angle glaucoma (POAG) who were already on benzalkonium chloride (BKC)-preserved latanoprost for a minimum of three months were enrolled. The age of patients ranged from 47 years to 88 years. Majority of the POAG patients were in the range of 61 to 70 years (Figure 1). The mean age was 66.9±10.56 years. Out of the 30 subjects enrolled in this study, 23 were males (76.67%) and 7 were females (23.33%) indicating a male to female ratio of about 3:1 (Figure 2).

At baseline, the mean IOP in POAG patients who were on treatment with BKC-preserved latanoprost was 15.57±0.85mmHg. The patients were then switched to BKC-free latanoprost. At 6 and 12 weeks of follow-up, their IOP was recorded again. Mean IOP at 6 weeks and 12 weeks in POAG patients after starting treatment with BKC-free latanoprost was 15.40±0.89mmHg and 15.30±0.70mmHg respectively (Figure 3).

DISCUSSION
Reduction of IOP is the core element of treatment of glaucoma. Good IOP control is necessary for adequate and efficient management and long term prognosis. The purpose of present study was to compare the extent of IOP reduction with BKC-preserved latanoprost versus
BKC-free latanoprost in patients of primary open angle glaucoma (POAG).

The present study found no statistically significant change in baseline IOP with BKC-preserved therapy as compared to IOP after 12 weeks of BKC-free therapy. IOP changed from 15.57±0.85 at baseline to 15.40±0.89 at 6 weeks to 15.30±0.70 at 12 weeks. p value was not found to be statistically significant at both the time points. Wang et al in 2013 did a meta-analysis of five studies and did not find any difference in IOP control between BKC-preserved and BKC-free therapies. Goldberg et al in 2015 conducted a study to evaluate the influence of BKC-free treatment on IOP and found non-significant results as compared to pre-treatment IOP values. Similar kind of results were observed by Miyashiro, Hamacher and Walimbe.

In contrast, in a study conducted by Hommer et al in 2011 a significant decrease was observed in IOP with preservative-free tafluprost as compared to preserved medication after a period of 12 weeks.

The study is entangled with its own limitations owing to its open-label design, lesser number of subjects and a shorter period of follow-up.

CONCLUSION

It has thus been observed that BKC-free therapies achieve adequate IOP control and are equally effective as BKC-preserved therapies in the management of glaucoma. Since BKC has been playing a havoc in quality of life of glaucoma patients, it is wise to replace BKC-preserved medications with BKC-free anti-glaucoma therapies which will not only be effective in lowering IOP but also prevent the occurrence of OSD. The pharmaceutical sector has already introduced BKC-free therapies into the market; though other alternatives for BKC are also being sought for.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Grierson I. The patient with primary open-angle glaucoma. Practitioner. 2000;244:654-8.
2. Marquiss JE, Whitson JT: Management of glaucoma: focus on pharmacological therapy. Drugs and Aging. 2005;22(1):1-21.
3. Guidance for industry-container and closure system integrity testing in lieu of sterility testing as a component of the stability protocol for sterile products. Rockville, MD, USA: Food and Drug Administration. 2008 Feb. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM146076.pdf. Cited 2016 Sep 24.
4. He XG. Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs. Zhonghua Yan Ke Za Zhi., 2011 Feb;47(2):101-4.
5. Jaenen N, Baudouin C, Poliquen P. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341-9.
6. Tomic M, Kaselman S, Soldo KM, Rabatic JS. How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome. Biomed Res Int. 2013;2013:1-7.
7. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511-9.
8. Chung SH, Lee SK, Cristol SM. Impact of short-term exposure of commercial eye drops preserved with benzalkonium chloride on precorneal mucin. Mol Vis. 2006;12:415-2.
9. Clouzeau C, Godfroy D, Riancho L, Rostène W, Baudouin C, Brignole-Baudouin F. Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. Molecular Vision. 2012;18:851-63.
10. Chang C, Zhang AQ, Kagan DB, Liu H, Hutnik CM. Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost. Clin Experimental Ophthalmology. 2015;43:164-72.
11. Gassett AR, Ishii Y, Kaufman HE, Miller T. Cytotoxicity of ophthalmic preservatives. AM J Ophthalmol. 1974;78:98-105.
12. Yalvaç IS, Gedikgölü G, Karagöz Y, Akgün U, Nurözler A, Koç F. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995 Jun;73(3):246-8.
13. Martone G, Frezzotti P, Tosi GM. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147(4):725-35.
14. Uusitalo H, Chen E, Pfeiffer N. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta ophthalmol. 2010;88(3):329-36.
15. Shehata AM. Preserved prostaglandin analog and ocular surface disorders in open-angle glaucoma. Med J Cairo Univ. 2015;83(1):109-14.
16. Wang YQ, Wang X, Liu P. Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride. Asian Pacific Journal of Tropical Medicine. 2013:1004-8.
17. Goldberg I, Graham SL, Crowston JG, d’Mellow G. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin Exp Ophthalmol. 2015;43(3):214-20.
18. Miyashiro MJ, Lo SC, Stewart JA, Stewart WC. Efficacy, safety and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients. Clin Ophthalmol. 2010;4:1355-9.

19. Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamic analysis. Acta Ophthalmologica. 2008;86(s242):14-19.

20. Walimbe T, Chelerkar V, Bhagat P, Joshi A, Raut A. Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma. Clin Ophthalmol. 2016;10:821-7.

21. Hommer A, Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative free tafluprost. Clinical Ophthalmol. 2011;5:623-31.

**Cite this article as:** Kaur A, Palta S, Chhabra H, Singh G, Gupta A. Effect of benzalkonium chloride-preserved latanoprost and benzalkonium chloride-free latanoprost on intraocular pressure in patients of primary open angle glaucoma. Int J Res Med Sci 2018;6:2495-8.